This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Same Problems In "New" Research On Autism And Vaccines

"New" study from DeStefano et al., rehashes flawed data - says SafeMinds

WASHINGTON, April 8, 2013 /PRNewswire-USNewswire/ -- A new book chapter on statistical methods in Recent Advances in Autism Spectrum Disorders by University of Northern Iowa researchers, DeSoto and Hitlan[1] documents major methodological flaws in the data set said to disprove the link between Thimerosal-preserved vaccines and autism by Price, et al.[2]   More recently DeStefano et al. [3] used the same data set while attempting to disprove a link between the number of vaccines and autism .

"Both researchers tested whether any increased risk of autism was associated with increased exposures via vaccination.  To do so, they must compare different levels of exposure.  They failed to do so when they matched cases to controls on birth-year and HMO.  Birth-year, by itself, defines exposure level and HMOs further ensures similarity guaranteeing cases and controls were nearly identical on the exposure," said lead author Dr. Catherine DeSoto.  "This is a design flaw called overmatching, it forces cases and controls to be artificially similar and renders the results invalid."

The number, type and timing of vaccines US children receive is a function of birth-year. Formulations purchased and administered would be the same within a given HMO.    

"By matching on birth year and HMO, they eliminated the variability right from the start," said Sallie Bernard, President of SafeMinds.  "Here's a perfect example of the cascading impact from problem data analysis. The same statistical flaws in Price's 2010 research resurface in De Stefano's 2013 research."

"Once again, media reported exactly what CDC released last week without critically reviewing the information," said Eric Uram, Executive Director at SafeMinds. 

Prior to approving Price et al. research, an appointed panel reviewed the study methodology raising design concerns.  Ultimately, the Centers for Disease Control and Prevention (CDC) National Immunization Program dismissed them.  In 2010, SafeMinds challenged the  Price et al., article's claims by highlighting flaws related to errors in the design. [4]  "Peer reviewers should reach agreement," concluded Bernard. "With Price, final approval processes were tipped to accept flawed methods."

SafeMinds maintains listings on peer reviewed research performed by independent scientists documenting neural risks associated with thimerosal and vaccination.  Reporters are encouraged to review and then contact the doctors and scientists doing high-quality work on the issues.[5]

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs